Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

导出 OA

翻译打印收藏纠错

作者： Tulio E,Rodriguez ^[1] ; Parameswaran,Hari ^[2] ; Patrick J,Stiff ^[3] ; Scott E,Smith ^[3] ; Danielle,Sterrenberg ^[4] ; David H,Vesole ^[5]

作者单位： Division of Hematology and Oncology, Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois. Electronic address: trodriguez@lumc.edu. ^[1] Department of Medicine and Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin. ^[2] Division of Hematology and Oncology, Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois. ^[3] Division of Hematology and Oncology, Department of Medicine, Loyola University Medical Center, Maywood, Illinois. ^[4] Multiple Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey; Multiple Myeloma Program, MedStar Georgetown University Hospital, Washington, DC. ^[5]

关键词 Bortezomib Busulfan Conditioning regimen Melphalan Multiple myeloma Stem cell transplantation